What is StimOxyGen?
StimOxyGen is at the forefront of developing advanced therapeutic systems designed to address the critical challenge of hypoxia within solid tumors. Their core innovation lies in a novel pH-sensitive nanoparticle formulation engineered to generate molecular oxygen in these oxygen-deprived tumor environments. This mechanism is crucial for improving the effectiveness of established cancer therapies, including radiotherapy and chemotherapy. The company's work, supported by scientific collaborations with Ulster University, targets significant unmet clinical needs in oncology, particularly for patients with treatment-resistant tumors.
How much funding has StimOxyGen raised?
StimOxyGen has raised a total of $1.9M across 1 funding round:
Other Financing Round
$1.9M
Other Financing Round (2025): $1.9M with participation from Clarendon Fund Managers, QUBIS, Innovate UK Business Connect, and DSW Ventures
Key Investors in StimOxyGen
Clarendon Fund Managers
Clarendon Fund Managers is a venture capital firm based in Belfast that specializes in providing equity finance to growth-oriented businesses in Northern Ireland. They manage significant regional VC funds and have a history of investing in over 100 companies, typically providing initial investments between £50,000 and £3 million.
QUBIS
QUBIS is an organization that partners with academic entrepreneurs to commercialize research from Queens University, Belfast, focusing on creating spinoff companies in sectors like life sciences and digital technologies. They have supported over 105 companies and raised substantial capital for their portfolio.
Innovate UK Business Connect
Innovate UK Business Connect, formerly Innovate UK KTN, serves as a crucial connector, linking innovators with new partners and opportunities to accelerate the development of real-world solutions.
What's next for StimOxyGen?
With this substantial enterprise-level backing, StimOxyGen is strategically positioned for accelerated growth and the scaling of its therapeutic technologies. The major strategic investment indicates strong confidence from its backers in the company's potential to disrupt the cancer treatment landscape. Future endeavors will likely focus on advancing its lead product through further development stages, potentially including clinical trials, and expanding its market reach. The company's commitment to innovation in oncology therapeutics suggests a trajectory aimed at significant clinical impact and commercial success.
See full StimOxyGen company page
